Cataracts Clinical Trial
Official title:
The Incidence of Glistenings in the 2017 Generation of Hydrophobic Acrylic Lenses Manufactured by Alcon and Abbott Medical Optics
Verified date | December 2023 |
Source | University of Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to seek academic/non-industry research funding support to independently investigate the incidence and density of lens glistenings in cataract patients who are implanted with the latest generations of intraocular lenses (IOL) manufactured by Alcon and AMO Medical Optics.
Status | Terminated |
Enrollment | 22 |
Est. completion date | March 31, 2023 |
Est. primary completion date | March 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients consulting 5 surgeons for cataract surgery in the surgeon's primary offices - Patients aged 18 years or older - Patients who signed the consent form Exclusion Criteria: - Individuals who cannot understand English in either written or verbal form and do not have language assistance available (e.g. from family members, friends) - Patients with co-existing condition of corneal disease - Patients with co-existing condition of uveitis - Patients with co-existing condition of optic nerve disease - Patients with co-existing condition of macular disease - Patients with co-existing condition of diabetes - Patients with co-existing condition of severe glaucoma (i.e. C/D ratio >=0.9 AND the patient is on glaucoma treatment) - Patients with prior refractive surgery - Patients with complications of cataract surgery occurred during or after surgery |
Country | Name | City | State |
---|---|---|---|
Canada | Kensington Eye Institute | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University of Toronto | Kensington Eye Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and density (severity) of glistenings at 18-month follow-up visit | To determine if glistenings develop, eyes are dilated and examined. Photographs of the IOLs will be taken with a slit lamp camera for documentation. These photographs will then be assessed for glistenings in two ways: first by trained ophthalmology staff, and second using the ImageJ software
Glistenings will be counted and graded on a scale of 0 to 5+ as following: 0. No glistening Less than 10 glistenings 10 to 25 glistenings 25 to 50 glistenings 50 to 100 glistenings Greater than 100 glistenings |
18-month follow-up | |
Secondary | Visual acuity in eyes with glistenings at 18-month follow-up visit | Best corrected visual acuity: acuteness/clearness of vision. This will be tested with the ETDRS (early treatment diabetic retinopathy study) chart. | 18 month follow-up | |
Secondary | Contrast sensitivity in eyes with glistenings at 18-month follow-up visit | Contrast sensitivity: the ability of the visual system to distinguish between an object and its background. This will be tested with the Vector Vision CSV-1000HGT. | 18 month follow-up | |
Secondary | Glare disability in eyes with glistenings at 18-month follow-up visit | Glare disability: the difficulty seeing in the presence of very bright light such as night-time lighting or sunshine. This will be tested using the Brightness Acuity Tester (BAT). | 18 month follow-up | |
Secondary | Visual acuity in eyes with glistenings at 12-month follow-up visit | Best corrected visual acuity: acuteness/clearness of vision. This will be tested with the ETDRS (early treatment diabetic retinopathy study) chart | 12-month follow-up | |
Secondary | Contrast sensitivity and glare disability in eyes with glistenings at 12-month follow-up visit | Contrast sensitivity: the ability of the visual system to distinguish between an object and its background. This will be tested with the Vector Vision CSV-1000HGT. | 12-month follow-up | |
Secondary | Glare disability in eyes with glistenings at 12-month follow-up visit | Glare disability: the difficulty seeing in the presence of very bright light such as night-time lighting or sunshine. This will be tested using the Brightness Acuity Tester (BAT). | 12-month follow-up | |
Secondary | Visual acuity in eyes with glistenings at 6-month follow-up visit | Best corrected visual acuity: acuteness/clearness of vision. This will be tested with the ETDRS (early treatment diabetic retinopathy study) chart. | 6-month follow-up | |
Secondary | Contrast sensitivity in eyes with glistenings at 6-month follow-up visit | Contrast sensitivity: the ability of the visual system to distinguish between an object and its background. This will be tested with the Vector Vision CSV-1000HGT. | 6-month follow-up | |
Secondary | Glare disability in eyes with glistenings at 6-month follow-up visit | Glare disability: the difficulty seeing in the presence of very bright light such as night-time lighting or sunshine. This will be tested using the Brightness Acuity Tester (BAT). | 6-month follow-up | |
Secondary | Incidence of glistenings at 12-month follow-up visit | To determine if glistenings develop, eyes are dilated and examined. Photographs of the IOLs will be taken with a slit lamp camera for documentation. These photographs will then be assessed for glistenings in two ways: first by trained ophthalmology staff, and second using the ImageJ software
Glistenings will be counted and graded on a scale of 0 to 5+ as following: 0. No glistening Less than 10 glistenings 10 to 25 glistenings 25 to 50 glistenings 50 to 100 glistenings Greater than 100 glistenings |
12-month follow-up | |
Secondary | Incidence of glistenings at 6-month follow-up visit | To determine if glistenings develop, eyes are dilated and examined. Photographs of the IOLs will be taken with a slit lamp camera for documentation. These photographs will then be assessed for glistenings in two ways: first by trained ophthalmology staff, and second using the ImageJ software
Glistenings will be counted and graded on a scale of 0 to 5+ as following: 0. No glistening Less than 10 glistenings 10 to 25 glistenings 25 to 50 glistenings 50 to 100 glistenings Greater than 100 glistenings |
6-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06005675 -
User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
|
||
Active, not recruiting |
NCT01382641 -
Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery
|
Phase 4 | |
Completed |
NCT01382823 -
Laser Cataract Surgery With the Femtosecond Laser Technology
|
Phase 4 | |
Completed |
NCT05991960 -
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
|
||
Active, not recruiting |
NCT05574959 -
Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V
|
N/A | |
Completed |
NCT02492659 -
Clinical Research of Femtosecond Laser-Assisted Cataract Surgery
|
N/A | |
Completed |
NCT01279031 -
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
|
Phase 4 | |
Completed |
NCT01021761 -
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT01061463 -
Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study
|
N/A | |
Completed |
NCT01001806 -
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT00999492 -
Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront
|
Phase 4 | |
Completed |
NCT00542581 -
Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.
|
N/A | |
Completed |
NCT03708367 -
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
|
N/A | |
Completed |
NCT05575063 -
Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)
|
N/A | |
Recruiting |
NCT05531292 -
PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002
|
N/A | |
Completed |
NCT05058274 -
Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
|
||
Completed |
NCT05053399 -
Evaluation of the TECNIS Symfony® Toric Intraocular Lens
|
N/A | |
Recruiting |
NCT02639845 -
Eye Drop Application Monitor, Pilot Study
|
N/A | |
Completed |
NCT01684007 -
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
|
N/A | |
Completed |
NCT00827073 -
Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery
|
N/A |